Asieris Pharmaceuticals
Manufacturing · Pennsylvania, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
201 King of Prussia Rd Ste 650, Radnor, ...Website
www.asieris.comRevenue
$14.4 MillionIndustry
About Asieris Pharmaceuticals
Asieris Pharmaceuticals is dedicated to improving human health and preserving patients' dignity through innovative therapies focused on genitourinary tumors and women's health. The company offers products such as Vesique® (APL-1202) and Cevira® (APL-1702), with a strong emphasis on urologic oncology and a robust gynecology pipeline. Asieris engages in global partnerships and collaborations to enhance its research and development capabilities. Their mission is to provide integrated diagnosis and treatment solutions while addressing both early- and late-stage medical needs.Explore more
Asieris Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Asieris Pharmaceuticals
Compare insights from companies similar to Asieris Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Asieris Pharmaceuticals Tech Stack
A closer look at the technologies used by Asieris Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Asieris Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Asieris Pharmaceuticals is dedicated to improving human health and preserving patients' dignity through innovative therapies focused on genitourinary tumors and women's health. The company offers products such as Vesique® (APL-1202) and Cevira® (APL-1702), with a strong emphasis on urologic oncology and a robust gynecology pipeline. Asieris engages... Read More
